Article
A Real-World Pharmacovigilance Study of Ceftazidime/avibactam: Data Mining of the FDA Adverse Event Reporting System (FAERS) Database
2024-01-10
Abstract excerpt
<title>Abstract</title> <p>Introduction Ceftazidime/avibactam (CAZ/AVI) is a combination of a well-known third-generation, broad-spectrum cephalosporin with a new beta-lactamase inhibitor that has been approved for the treatment of various infectious diseases (especially MDR-GNB infections) by the FDA. Aim The present study extensively assessed real-world CAZ/AVI-related adverse events (AEs) through data mining...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- c4fae95e-622c-536a-8b04-4ec6372c17e8
- DOI
- 10.21203/rs.3.rs-3802796/v1
